MARKET

VRTX

VRTX

Vertex Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

212.52
-4.52
-2.08%
Opening 14:40 02/25 EST
OPEN
215.80
PREV CLOSE
217.04
HIGH
217.40
LOW
210.50
VOLUME
990.04K
TURNOVER
--
52 WEEK HIGH
306.08
52 WEEK LOW
197.47
MARKET CAP
55.25B
P/E (TTM)
20.63
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Vertex to Present at the Cowen Health Care Conference on March 2
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Health Care Conference on Tuesday, March 2, 2021 at 9:50 a.m. ET.
BusinessWire · 1d ago
Cramer Weighs In On Canopy Growth, Dish Network And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said the negative commentary about Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is wrong.
Benzinga · 1d ago
Cramer's lightning round: I want to be a buyer of Canopy Growth
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
CNBC.com · 1d ago
Cough Hypersensitivity Syndrome Treatment Market : Industry Insights, Major Key Players and Current Trends Analysis
Comserve · 2d ago
DJ Vertex Pharmaceuticals Raised to Outperform From Neutral by Baird
Dow Jones · 2d ago
DJ Vertex Pharmaceuticals Price Target Raised to $252.00/Share From $220.00 by Baird
Dow Jones · 2d ago
--Analyst Actions: Baird Upgrades Vertex Pharmaceuticals to Outperform From Neutral, Adjusts Price Target to $252 From $220
MT Newswires · 2d ago
Global Cystic Fibrosis Market Size 2021 Top Manufacturers, Share, Growth Factor, Latest Trends, Type and Application Forecast 2026
Feb 23, 2021 (The Expresswire) -- Global “Cystic Fibrosis Market” report is a fact-based market research and important information to companies, competitors,...
The Express Wire · 2d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRTX. Analyze the recent business situations of Vertex Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 27 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRTX stock price target is 284.73 with a high estimate of 347.00 and a low estimate of 250.00.
EPS
Institutional Holdings
Institutions: 1.39K
Institutional Holdings: 251.58M
% Owned: 96.78%
Shares Outstanding: 259.96M
TypeInstitutionsShares
Increased
364
21.42M
New
265
-1.75M
Decreased
307
23.22M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.29%
Pharmaceuticals & Medical Research
-1.33%
Key Executives
Chairman/Director
Jeffrey Leiden
President/Chief Executive Officer/Director
Reshma Kewalramani
Executive Vice President/Chief Administrative Officer
Charles Milstein
Chief Financial Officer/Executive Vice President
Charles Wagner
Executive Vice President/Chief Administrative Officer
Michael Parini
Executive Vice President/Chief Scientific Officer
David Altshuler
Executive Vice President
Stuart Arbuckle
Executive Vice President
Carmen Bozic
Executive Vice President
Gerald Bruce
Executive Vice President
Amit Sachdev
Senior Vice President
Kimberly White
Senior Vice President/Controller
Paul Silva
Senior Vice President
John Gray
Director
David Greenway
Senior Vice President
Nia Tatsis
Lead Director/Independent Director
Bruce Sachs
Independent Director
Sangeeta Bhatia
Independent Director
Lloyd Carney
Independent Director
lloyd Carney
Independent Director
Alan Garber
Independent Director
Terrence Kearney
Independent Director
Yuchun Lee
Independent Director
Margaret McGlynn
Independent Director
Diana McKenzie
Independent Director
William Young
  • Dividends
  • Splits
  • Insider Activity
No Data
About VRTX
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Webull offers kinds of Vertex Pharmaceuticals Incorporated stock information, including NASDAQ:VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.